The European Medicines Agency (EMA) has started a review of canagliflozin, dapagliflozin and empagliflozin, which are diabetes medicines known as SGLT2 inhibitors. This was requested by the European Commission following several reports of diabetic ketoacidosis in patients on SGLT2 inhibitor treatment for Type 2 diabetes. EMA will now review all available data on the risk of diabetic ketoacidosis (DKA) with SGLT2 inhibitors and consider whether any changes are needed in the way these medicines are used in the EU.
The InDependent Diabetes Trust [IDDT] is all too aware of the difficulties that children with diabetes and their parents face in everyday life when managing the condition. One area that proves particularly problematic is managing the condition at school. With this in mind, IDDT has produced a new, FREE booklet, the Parents Passport for Schools.
The National Paediatric Audit report by the Royal College of Paediatrics and Child Health, March 2015, has shown that in England and Wales only 16.1% of young people aged 12 years and older are receiving the 7 annual checks that every child with diabetes should have. This is a slight improvement from the last audit but still very worrying.
It is important that people have a fully informed choice of insulin so that they can choose the type of insulin and the regime that suits them and their lifestyle.